Eidos Therapeutics raised to $51 from $28 at Roth Capital

Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics (EIDX) to $51 from $28 driven by an increase in AG10’s annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80% after Pfizer’s (PFE) tafamadis received U.S. approval with a high sticker price of $225,000, two months ahead of schedule. The analyst believes this makes life easier for Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial. Rahimi reiterates a Buy rating on Eidos Therapeutics shares.
https://thefly.com/landingPageNews.php?id=2904755

Edit